-transparent.png){kind=logo}
Amidated fragments 1 to 29 of human growth hormone releasing factor, (GRF1-29NH2), were designed to encompass modifications that could prevent degradation by exopeptidases. The NH2-terminus was blocked by either N-methylation of Tyr1 or by introduction of NMeDAla2 while the COOH-terminus was blocked by an N-ethylamide. Other substitutions such as Nle in position 27 for methionine conferred stability toward air oxidation while Asn28, an amino acid substitution found in rat GRF, seemed to confer stronger binding affinity to the GRF receptor. Potency in vitro and duration of action in vivo of [NMeTyr1,Nle27,Asn28]hGRF1-29NHEt (4SG-29) were compared to those of hGRF1-40OH. 4SG-29 was found to be both ten times more potent than hGRF1-40)OH and exhibit significantly extended duration of action.
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
January 1988,
Peptide research,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
April 1979,
Clinical endocrinology,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
January 1996,
Fertility and sterility,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
August 1989,
Proceedings of the National Academy of Sciences of the United States of America,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
August 1977,
Nature,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
January 2021,
Frontiers in endocrinology,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
September 2003,
Advanced drug delivery reviews,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
December 2013,
Paediatric drugs,
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
December 1985,
British medical journal (Clinical research ed.),
J Rivier, and
C Rivier, and
R Galyean, and
G Yammamoto, and
W Vale
January 1992,
Peptide research,
